Bristol-Myers Squibb to Buy Amylin

NEW YORK ( TheStreet) -- Bristol-Myers Squibb ( BMY) announced late Friday that it's purchasing diabetes drugmaker Amylin Pharmaceuticals ( AMLN) in a deal valued at about $7 billion.

In a news release, the companies said Bristol-Myers will pay $31.00 a share in cash for San Diego-based Amylin.

That adds up to about $5.3 billion.

Including Amylin's net debt and a payment obligation to Eli Lilly & Co. ( LLY), however, the deal's total value rises to about $7 billion, the companies said.

The purchase price offers a 9.9% premium of to Amylin's closing share price Friday of $28.20.

The boards of Bristol-Myers and Amylin have approved the transaction.

In addition, following the consummation of the deal, New York-based Bristol-Myers plans expand its diabetes partnership with AstraZeneca PLC ( AZN). The companies will collaborate on developing and marketing Amylin's portfolio of drugs.

AstraZeneca will pay Bristol-Myers Squibb approximately $3.4 billion in cash, and the two partners will split profits and losses from the collaboration.

Shares of Bristol-Myers Squibb closed Friday up 87 cents at $35.95. Shares of AstraZeneca ended the session up 36 cents at $44.75.

This article was written by a staff member of TheStreet.

More from Stocks

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Complying With GDPR Could Be Costly for Facebook, Google and Other Tech Giants

Complying With GDPR Could Be Costly for Facebook, Google and Other Tech Giants

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

North Korea, Apple, GPDR and Gap - 5 Things You Must Know

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Market Can't Handle the Wild Ride: Cramer's 'Mad Money' Recap (Thursday 5/24/18)

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation

Replay: Jim Cramer on North Korea, Oil Prices, Apple and Carnival Corporation